Overall and event-free survival of patients with D816 mutations in subgroups with t(8;21) or with intermediate karyotype. OS and EFS for patients with mutated or nonmutated KIT-D816. (A) Only t(8;21) subgroup. (B) Patients with intermediate karyotype. (C) All AML. Figure shows Kaplan-Meier analyses for the patient numbers indicated. “Median” indicates median survival time; survival curves were compared using double-sided log rank test.